Pyrimidine-based dual-target inhibitors targeting epidermal growth factor receptor for overcoming drug resistance in cancer therapy (2006-present)
Y An, X Lv, S Xu, H Li, P Zheng, W Zhu… - European Journal of …, 2025 - Elsevier
The epidermal growth factor receptor (EGFR) is a pivotal member of the epidermal growth
factor receptor family, exerting crucial regulatory influence on cellular physiological …
factor receptor family, exerting crucial regulatory influence on cellular physiological …
A decade's overview of 2‐aminothiophenes and their fused analogs as promising anticancer agents
DG Darwish, HAM El‐Sherief… - Archiv der …, 2024 - Wiley Online Library
Over the past decades, cancer has been a challenging domain for medicinal chemists as it
is an international health concern. In association, small molecules such as 2 …
is an international health concern. In association, small molecules such as 2 …
Discovery of EMD37, a 1, 2, 4-oxadiazole derivative, as a novel endoplasmic reticulum stress inducer with potent anticancer activity
Targeting endoplasmic reticulum (ER) stress presents a promising strategy in cancer
therapy. We previously reported a series of 1, 2, 4-oxadiazole derivatives that induced the …
therapy. We previously reported a series of 1, 2, 4-oxadiazole derivatives that induced the …
Hydrazinecarbonyl-thiazol-2-acetamides with pronounced apoptotic behavior: synthesis, in vitro/in vivo anti-proliferative activity and molecular modeling simulations
A new series of N-[4-(2-substituted hydrazine-1-carbonyl) thiazole-2-yl] acetamides was
synthesized and evaluated in vitro against six human cell lines as antitumor agents …
synthesized and evaluated in vitro against six human cell lines as antitumor agents …
Epidermal growth factor receptor mutations in breast Cancer: Therapeutic challenges and way forward
SR Shetty, T Kar, A Das - Bioorganic Chemistry, 2024 - Elsevier
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK) that is
upregulated in aggressive triple-negative breast cancer (TNBC). Ligands such as EGF, TGF …
upregulated in aggressive triple-negative breast cancer (TNBC). Ligands such as EGF, TGF …
[HTML][HTML] EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: A critical review
RM Raju, JA Jeffin, RN Manjunathaiah, A Justin… - Results in …, 2024 - Elsevier
Abstract Epidermal Growth Factor Receptor is a multifunctional receptor and is an important
member of tyrosine kinase family. Investigation on mechanism of tumour progression and its …
member of tyrosine kinase family. Investigation on mechanism of tumour progression and its …
[HTML][HTML] Deciphering the Complex Interplay of Long Noncoding RNAs and Aurora Kinases: Novel Insights into Breast Cancer Development and Therapeutic Strategies
MK Saadeldin, G Curigliano, AK Abdel-Aziz - Future Pharmacology, 2024 - mdpi.com
Breast cancer is the most common type of cancer globally and presents an escalating
problem and a huge burden on societies. Several strategies are implemented in clinics to …
problem and a huge burden on societies. Several strategies are implemented in clinics to …
Is Thienopyrimidine a Suitable Scaffold for HER2 Tyrosine Kinase Inhibitors?
SI Strøm - 2022 - ntnuopen.ntnu.no
HER2-positiv brystkreft er en kreftform med økt uttrykk av HER2-reseptoren, som fører til
ukontrollert cellevekst og celledeling. En behandlingsmetode for denne typen kreft er …
ukontrollert cellevekst og celledeling. En behandlingsmetode for denne typen kreft er …